|
CA2695613A1
|
|
Sulfonamide derivatives with therapeutic indications
|
|
WO2008001369A1
|
|
Use of cb2 receptor agonists for promoting neurogenesis
|
|
WO2007020631A2
|
|
Tetracyclic benzofuran derivatives with therapeutic activities
|
|
AU2006253734A1
|
|
Benzofuran derivatives with therapeutic activities
|
|
CN101076324A
|
|
Orally effective cannabinoid analogs
|
|
IL166805D0
|
|
Non-psychotropic cannabinoids for prevention of cognitive impairment
|
|
CA2507815A1
|
|
High enantiomeric purity dexanabinol for pharmaceutical compositions
|
|
AU2003256059A1
|
|
Non-psychotropic cannabinoids for prevention of cognitive impairment
|
|
AU2003245023A8
|
|
Non-psychotropic cannabinoids for prevention of cognitive impairment
|
|
US7235584B2
|
|
Non-psychotropic cannabinoids
|
|
IL163877D0
|
|
Dexanabinol and dexanabinol analogsregulate inflammation related genes
|
|
EP1469842A2
|
|
Bicyclic cb2 cannabinoid receptor ligands
|
|
CN1627939A
|
|
Bicyclic CB2 cannabinoid receptor ligands
|
|
IL153277D0
|
|
High enantiomeric purity dexanabinol for pharmaceutical compositions
|
|
IL148736D0
|
|
Dexanabinol and dexanabinol analogs which regulate inflammation related genes
|
|
IL147941D0
|
|
Bicyclic cb2 cannabinoid receptor ligands
|
|
EP1785417A2
|
|
Novel non-psychotropic cannabinoids
|
|
IL152610D0
|
|
Novel non-psychotropic cannabinoids
|
|
HU0301628A2
|
|
Novel non-psychotropic cannabinoids
|
|
IL136946D0
|
|
Novel non-psychotropic cannabinoids
|
